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Abstract
Background: New therapeutic strategies in muscular dystrophies will make a difference in prognosis only if they
are begun early in the course of the disease. Therefore, we investigated factors that influence the time to diagnosis
in muscle dystrophy patients.
Methods: A sample of 101 patients (mean age 49 years; range 19-80; 44% women) with diagnosed muscle
dystrophies from neurological practices and the neuromuscular specialty clinic in Berlin, Germany, was invited to
participate. Time from first consultation to diagnosis, subspecialty of physician, and sociodemographic data were
assessed with self-report questionnaires. The association between time to diagnosis and potential predictors
(subspecialty of initially consulted physician, diagnoses, gender, and age at onset) was modeled with linear
regression analysis.
Results: The mean time span between first health-care contact and diagnosis was 4.3 years (median 1). The
diagnostic delay was significantly longer if patients were initially seen by a non-neurological specialist compared to
a general practitioner (5.2 vs. 3.5 years, p = 0.047). Other factors that were independently associated with
diagnostic delay were female gender and inherited muscle disease.
Conclusion: Action to improve clinical awareness of muscle diseases in non-neurological specialists is needed.
Background
Our mechanistic understanding of muscular dystrophies
and inherited myopathies has improved remarkably dur-
ing the last decade [1]. This progress leads to a much
higher level of diagnostic accuracy and to the possibility
of new therapeutic strategies [2,3]. To benefit from this
progress, the diagnosis of a muscle disorder must be
made early. However, certain factors may contribute to
delay in diagnosis. First, the term “neuromuscular disor-
der” encompasses more than 300 different rare chronic
diseases. Second, myopathies and muscular dystrophies
present with unspecific complaints, such as difficulty
climbing stairs, heaviness in the legs, myalgias, or
cramps. The time course is often slow and years may
pass before a significant worsening is perceived. Many
different subspecialties from primary care, internal
medicine, orthopedics, rheumatology, or psychosomatic
medicine may be consulted and may give various tenta-
tive diagnoses before the patient is referred to a neurol-
ogist. For example, fatigue may be mistakenly
interpreted as lack of exercise or diminished motivation.
An elevated level of creatine kinase level, when deter-
mined at all, can be misinterpreted as heart disease.
Some health care systems, like the British, allow access
to medical specialists only after consultation of a general
practitioner (GP). In other medical systems, such as the
one in Germany, the choice is left to the patient
whether a GP or a specialist serves as the primary con-
tact. In any event, a neurologist is seldom the first
choice.
The medical and economic consequences of these dif-
ferent systems are poorly studied. The time from the
first consultation to the correct diagnosis in patients
with amyotrophic lateral sclerosis (ALS) [4,5] has been
investigated, as has the course of Duchenne muscle dys-
trophy (DMD) patients [6]. Other studies have examined
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the time from first onset to diagnosis in patients with
myasthenia gravis [7], body inclusion myositis (IBM) [8],
and Becker’s congenital myotonia [9]. The experience in
ALS patients suggests that gender and subspecialty of
medical doctors may contribute to the diagnostic delay
[4]. However, there are few data on the broad muscular
dystrophy spectrum in adult patients. We therefore
investigated factors that influence the time to diagnosis
in muscle dystrophy patients.
Methods
Study setting and sample
Patients were recruited into the study from neurologists
in private practice, the patient support group of the
German Muscle Society, or from the neuromuscular
specialty clinic at the Charité University Hospital, Berlin.
Inclusion criteria were a diagnosis of muscle dystrophy,
and age above 18 years. There were no patients with
DMD. All patients enlisted voluntarily in the study and
provided informed consent after due Institutional
Review Board approval by the Charité - Universitätsme-
dizin Berlin.
Materials and procedure
We gave the patients standardized self-report question-
naires. We asked them about their diagnosis, the initial
choice of medical practitioner, the time interval between
first medical consultation and the definitive diagnosis,
and the nature and number of referrals. Questionnaires
were anonymized and approved by the data security
engineer. The response rate was 104 out of 130 (80%).
Three patients were excluded from the analysis because
they failed to report on the time of the first medical
consultation and time of diagnosis. Thus, our final sam-
ple comprised 101 adult patients (44 women). The med-
ical subspecialties were divided into three categories: (1)
general practitioners (GP), (2) non-neurological specia-
lists (orthopedic surgeons, internists, physical medicine
and rehabilitation specialists, psychosomatic medicine,
and rheumatologists), and (3) neurologists.
Data analysis
Comparisons among men and women were made using
the Mann-Whitney U test or the Student’s t-test for
continuous variables depending on the distribution of
data, and the c2-square test for categorical variables.
Mann-Whitney U test (two groups) or Kruskal-Wallis
test (more than two groups) were used to determine dif-
ferences in time to diagnosis among different subspecial-
ties. Multiple linear regression analysis with forward
selection was performed to assess associations between
time to diagnosis and a set of predictors. A square root
transformation was fitted to the variable “time to diag-
nosis” to approximate the data to a normal distribution.
A two-tailed alpha level of 0.05 was considered signifi-
cant for all analyses. All analyses were performed using
SPSS 16.0 (SPSS Inc.; Chicago, IL).
Results
The average age of the 101 study participants was 48.9
years (SD = 14.5) with a range of 19 to 80 years. The
sample was relatively well educated with over 90% of
participants reporting a medium or high level of educa-
tion. More than half of the patients had an inherited
muscle disease, and in 36% of the patients, the onset of
disease occurred in childhood or adolescence (Table 1).
The primary health care step and time to diagnosis
Thirty eight patients first consulted a GP after the onset
of myopathy-related symptoms, whereas 48 patients
chose non-neurological specialists. Only 15 patients con-
sulted a neurologist as the primary health care step
(Table 1). These patients either had family members with
a hereditary muscle disorder or had an above-average
level of education (some were physicians themselves).
Even in this group, only 60% of the patients were diag-
nosed within one year. The mean time between first con-
sultation of a physician and the definite diagnosis was
4.3 years (MD = 1) (Table 1). The time to diagnosis
(Figure 1) was dependent on subspecialty of physician
with a significant difference between the three groups
(p = 0.021). When a neurologist or a GP was initially
consulted, the time from first visit to diagnosis was
3.4 years (MD = 0.5) and 3.5 years (MD = 1), respectively.
When a non-neurological specialist was the first medical
contact, the time to diagnosis increased to 5.2 years (MD
= 2.5). Subgroup analyses showed a significant difference
in diagnostic delay between a GP und non-neurological
specialists in that the GPs were better (p = 0.047) and
between neurologists and non-neurological specialists
(p = 0.016). After the initial consultation, 18 patients
were misdiagnosed and treated for prolonged periods for
some other presumed condition. Non-neurologists initi-
ally managed 17 of these 18 patients. GPs immediately
referred 17 (45%) of their patients to a neuromuscular
center, and 20 (53%) to a non-neurological specialist.
Gender differences in diagnostic delay
Forty-four percent of subjects were women. There were
no gender differences in education, age at onset, diag-
noses, or specialty of first consultation (Table 1). How-
ever, for women the time from first consultation
resulting from myopathy-related symptoms to diagnosis
was significantly longer compared to men (p = 0.014)
(Table 1). This effect was particularly striking when
non-neurological specialists were consulted in the first
instance (7.2 years for women vs. 3.2 years for men, p =
0.015) (Figure 2).
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Predictors for time to diagnosis
Results from univariable regression analyses showed that
age at onset, inherited muscle disease, female gender,
and subspecialty were significantly associated with time
to diagnosis (Table 2). Multiple regression analysis with
Table 1 Sample characteristics
Entire sample
(N = 101)
Men
(n = 57)
Women
(n = 44)
p
Age (yrs); mean ± SD 48.9 ± 14.5 49.2 ± 14.6 48.6 ± 14.8 0.854
Education level Low 7 (7.1%) 3 (5.4%) 4 (9.3%) 0.614
Medium 46 (46.5%) 28 (50.0%) 18 (41.9%)
High 46 (46.5%) 25 (44.6%) 21 (48.8%)
Age group at onset Childhood
/adolescence
36 (35.6%) 19 (33.3%) 17 (38.6%) 0.581
Adulthood 65 (64.4%) 66.7 (67%) 27 (61.4%)
Diagnoses Inherited muscle
diseases*
56 (55.4%) 31 (54.4%) 25 (56.8%) 0.807
Acquired muscle
diseases**
22 (21.8%) 10 (17.5%) 12 (27.3%) 0.240
SMA III and IV*** 14 (13.9%) 8 (14%) 6 (13.6%) 0.954
Time from first
consultation to
diagnosis (yrs);
mean (median)
4.3 (1.0) 2.9 (1.0) 6.1 (3.0) 0.014
First consultation Neurologists 15 (14.9%) 9 (15.8%) 6 (13.6%) 0.763
General
practitioners
38 (37.6%) 24 (42.1%) 14 (31.8%) 0.29
Non-neurological
specialists
48 (47.5%) 24 (42.1%) 24 (54.5%) 0.214
Note. SD = standard deviation.
*limb-girdle muscular dystrophies (MD), facioscapulohumeral MD, AD Emery Dreifuss MD, congenital myopathies, metabolic myopathies, channelopathies, no
patients with Duchenne MD are included.
**inclusion body myositis, polymyositis.
***spinal muscle atrophy.
Figure 1 Displayed are differences in diagnostic delay
according to medical subspecialty at first consultation. The
delay is longest for patients who first consulted a non-neurological
specialist (e.g. internist, orthopedics). Boxes display values between
25 and 75 percentile; outliers are indicated by stars.
Figure 2 Association between medical subspecialty at first
health care action, gender, and diagnostic delay is shown. Time
span between first medical consultation and diagnosis is increased
for patients initially seen by a non-neurological specialist. The delay
is longest for women who first consulted a non-neurological
specialist. Boxes display values between 25 and 75 percentile;
outliers are indicated by stars.
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forward selection, including type of muscle disease, edu-
cation, gender, subspecialty of first consultation, and age
at onset, revealed that only inherited muscle disease,
female gender, and subspecialty were independent pre-
dictors of time to diagnosis (Table 2).
Discussion
Our study found two key results. First, patients consult-
ing a non-neurological specialist experience a longer
delay in diagnosis, compared to patients who initially
consulted a neurologist or a GP. Second, for women,
the diagnostic delay was even longer than for men. Our
data showed that there was no difference in time to
diagnosis when initially either a neurologist or a GP was
consulted. Interestingly, first consulting another subspe-
cialty resulted in a significant diagnostic delay compared
to a neurologist or a GP. In Germany, the choice is left
to the patient as to whether a GP or a specialist serves
as the primary contact. Other health care systems allow
access to a specialist only after consultation with a GP.
Leaving the patient with the decision to choose a medi-
cal subspecialist as the primary point of contact with
the medical profession has profound effects on the diag-
nostic course. Our data support the usefulness of a sys-
tem that first requires the consultation of a GP,
followed by assignment to a specialist. The GP appeared
to be well qualified by training to direct the patient to
the correct subspecialty.
Our results are consistent with findings indicating that
patients with predominantly adult-onset muscle diseases
experience a diagnostic delay that is several years longer
than the life-span observed in boys with DMD (mean
delay 1 year 11 months) [10,11]. One reason may be the
more benign and subtle course of many muscular dys-
trophies and myopathies, which may be associated with
less-obvious symptoms than dystrophinopathies. Motor
neuron diseases such as ALS progress more rapidly and
are correctly diagnosed within a time span of 11 and
13 months, as indicated by other studies [4,5]. Another
reason may be related to the lower prevalence of limb
girdle muscular dystrophies and other myopathies, com-
pared to DMD [12]. This state of affairs could lead to a
very low level of clinical awareness. Generally, rare dis-
eases are less thoroughly emphasized in medical school.
Moreover, the infrequent contact with muscle diseases
in clinical praxis may not sufficiently consolidate these
cases in the physician’s memory. Inherited diseases
showed a longer time from first contact to definite diag-
nosis, compared to acquired diseases. Often, inherited
muscle diseases present with a subtle course, whereas
symptoms accelerate more rapidly in acquired diseases.
Although one would expect a higher awareness in
patients with affected relatives, patients often are not
aware that family members have the disease [13]. Alter-
natively, the disease may be less prevalent in the family
due to being passed on a recessive chromosome.
The diagnostic delay affected women more than men,
particularly when the women were initially seen by non-
neurological specialists. Several factors may contribute
to this effect. First, unspecific symptoms like heaviness
of the legs, tiredness, or cramps may not be taken as
seriously in women compared to men. We know from
other studies that symptoms such as fatigability are
more often attributed to psychological problems in
women than in men [14,15]. Also, men are physically
more active and therefore might be more quickly aware
of physical problems. In addition, men have a tendency
to wait longer until consulting a physician and are thus
more likely to present with a more advanced disease
[16], which then may be easier to diagnose.
We are aware of limitations. First, patients might dif-
fer in their ability to recall information about their first
Table 2 Associations with time to diagnosis: results from univariable and multiple regression analysis
Variable Univariable regression Multiple regression*
b** 95% CI p-value b** 95% CI p-value
Gender 0.276 0.202 - 1.127 0.005 0.281 0.212 - 1.152 0.008
Education 0.115 -0.166 - 0.616 0.257
Age at onset 0.234 0.101 - 1.069 0.018
Type of disease
Inherited muscle diseases 0.212 0.041 - 0.979 0.033 0.260 0.170 - 1.088 0.008
Acquired muscle diseases -0.165 -1.048 - 0.092 0.099
SMA III and IV -0.099 -1.031 - 0.343 0.323
Subspecialty
Neurologist -0.120 -1.071 - 0.261 0.230
General practitioner -0.113 -0.769 - 0.209 0.259
Non-neurological specialist 0.196 0.01 - 0.937 0.05 0.226 0.085 - 1.004 0.021
Note. b = standardized regression coefficient; CI = confidence interval; SMA = spinal muscle atrophy.
*multiple linear regression analysis with forward selection.
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consultation and the correct time point of the diagnosis.
Second, due to the rareness of muscular dystrophies,
our sample is comparatively small. Third, the waiting
time for an appointment was not assessed in this inves-
tigation. However, since waiting time for an appoint-
ment is usually less than three months in Germany, this
issue seems negligible.
Conclusions
Any future therapeutic strategy will probably only make
a real difference in prognosis if the treatment is begun
early in the course of the disease [17]. Whereas in DMD
patients pediatricians are primarily involved in terms of
newborn-screening and other related programs [18],
adult-onset muscle diseases can present to a variety of
medical subspecialties. Neurologists and neuromuscular
specialists should make an active effort to increase the
clinical awareness of muscle diseases among other medi-
cal specialties.
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